 First-in-Human Study of Companys CD137PD-L1 Tetravalent Bispecific Antibody Expands into Tumor Specific Indications First-in-Human Study of Companys CD137PD-L1 Tetravalent Bispecific Antibody Expands into Tumor Specific Indications 